Secukinumab in the treatment of psoriasis: patient selection and perspectives
Eric J Yang,1,2 Kristen M Beck,1 Wilson Liao1 1Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA Abstract: Secukinumab is a human monoclonal antibody targeti...
Guardado en:
Autores principales: | Yang EJ, Beck KM, Liao W |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9b7488745a654ceda2223efe2fd2ac39 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon S, et al.
Publicado: (2017) -
Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Aline Lissa Okita, et al.
Publicado: (2020) -
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck KM, et al.
Publicado: (2018) -
Targeting IL-23 in psoriasis: current perspectives
por: Fotiadou C, et al.
Publicado: (2018) -
Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges
por: el Hayderi L, et al.
Publicado: (2016)